Teriparatide is indicated for use in postmenopausal women with osteoporosis at high risk of fracture or a history of fracture ostoporotic, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other anti-osteoporotic available.
Teriparatide is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant of other anti-osteoporotic available.
Teriparatide is indicated for treating both men and women with osteoporosis associated with prolonged systemic corticosteroid therapy.
Teriparatide should not be prescribed to patients who are at increased risk of osteosarcoma. This includes those with Paget’s disease of bone or unexplained elevations of serum alkaline phosphatase, open epiphyses, or prior radiation therapy involving the skeleton.
FDA approval
Teriparatide was approved by the Food and Drug Administration (FDA) November 26, 2002, for the treatment of osteoporosis in men and postmenopausal women who are at high risk of having a fracture. The drug is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk of fracture.
Read more:Teriparatide
price
No comments:
Post a Comment